Description: Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Home Page: benitec.com
BNTC Technical Analysis
3940 Trust Way
Hayward,
CA
94545
United States
Phone:
510 780 0819
Officers
| Name | Title |
|---|---|
| Dr. Jerel A. Banks M.D., Ph.D. | Exec. Chairman & CEO |
| Ms. Megan Joan Boston BComm, CA, Dip., GAICD | Exec. Director |
| Mr. Bryan Dulhunty | Chief Financial Officer |
| Dr. Michael Graham | Head of Discovery & Founding Scientist |
| Dr. Craig Lewis | Chief Medical Adviser |
| Dr. Claudia Kloth | Sr. VP of Manufacturing |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2993 |
| Price-to-Sales TTM: | 57.2273 |
| IPO Date: | 2015-08-18 |
| Fiscal Year End: | June |
| Full Time Employees: | 18 |